Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is projected to release its results before the market opens on Thursday, March 19th. Analysts expect Armata Pharmaceuticals to post earnings of ($0.19) per share and revenue of $0.74 million for the quarter.

Armata Pharmaceuticals Price Performance

NYSEAMERICAN ARMP opened at $11.50 on Thursday. The stock has a market capitalization of $418.72 million, a PE ratio of -7.10 and a beta of 1.30. Armata Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $16.34. The business’s 50-day moving average is $8.14 and its 200 day moving average is $5.93.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ARMP. Jane Street Group LLC bought a new position in Armata Pharmaceuticals during the 4th quarter valued at about $108,000. Millennium Management LLC bought a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth approximately $164,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth approximately $177,000. Goldman Sachs Group Inc. purchased a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $284,000. Finally, State Street Corp lifted its position in Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after purchasing an additional 10,500 shares during the period. Hedge funds and other institutional investors own 3.57% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ARMP. HC Wainwright boosted their target price on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. JonesTrading assumed coverage on Armata Pharmaceuticals in a research note on Monday, January 5th. They issued a “buy” rating and a $15.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $15.00.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.